Cumberland Pharmaceuticals Inc (CPIX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Cumberland Pharmaceuticals Inc (CPIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10165)・商品コード:DATA904C10165
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:54
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Cumberland Pharmaceuticals Inc (Cumberland Pharma) is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products. Its primary target markets are hospital acute care, gastroenterology and cancer supportive care. The company offers branded prescription products under Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Ethyol, Totect, Hepatoren, Boxaban, Vasculan Portaban and RediTrex brand names. Cumberland Pharma promotes approved products through its hospital and gastroenterology sales forces in the US. It is also establishing a network of international partners to bring its products to patients in their countries. Cumberland Pharma is headquartered in Nashville, Tennessee, the US.

Cumberland Pharmaceuticals Inc (CPIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Cumberland Pharma to Acquire Vibative from Theravance Biopharma 12
Cumberland Pharma to Acquire Omeclamox-Pak from Gastro-Entero Logic 13
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 14
Partnerships 15
Cumberland Pharma and Poly Pharma Enter into Co-promotion Agreement 15
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 16
Cumberland Pharma Enters into Agreement with Gastoenterlogics 17
Cumberland Pharma Enters into Agreement with Piramal Critical Care 18
Cumberland Pharma Enters into Agreement with Clinigen 19
Cumberland And Harbin Gloria Enter Into R&D Agreement With Cumberland Emerging 20
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 21
Licensing Agreements 22
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 22
Cumberland Pharma Enters into Licensing Agreement with Nordic Group 23
Cumberland Pharma Enters Into Licensing Agreement With Sandor Medicaids For Caldolor 25
Harbin Gloria Pharma Enters Into Licensing Agreement With Cumberland Pharma For Acetadote and Caldolor 26
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 28
Cumberland Pharma Enters Into Licensing Agreement With SOHO Industri Pharmasi For Caldolor 29
Equity Offering 30
Cumberland Pharma Plans to Raise up to USD25 Million in Public Offering of Shares 30
Cumberland Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 31
Cumberland Pharmaceuticals Inc – Key Competitors 32
Cumberland Pharmaceuticals Inc – Key Employees 33
Cumberland Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 14, 2018: Cumberland Pharmaceuticals reports second quarter 2018 financial results 35
May 08, 2018: Cumberland Pharmaceuticals Reports First Quarter 2018 Financial Results 38
Mar 06, 2018: Cumberland Pharmaceuticals Reports 25% Revenue Growth For The Full Year 2017 40
Nov 07, 2017: Cumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter 42
Aug 08, 2017: Cumberland Pharmaceuticals Reports Double Digit Revenue Growth for the Fourth Consecutive Quarter 44
May 15, 2017: Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017 46
Mar 07, 2017: Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results 48
Corporate Communications 50
Sep 24, 2018: Cumberland Pharmaceuticals announces Senior Music Industry Executive joins its Board Of Directors 50
Aug 07, 2018: Cumberland Pharmaceuticals appoints new senior executive 51
Jul 24, 2018: Cumberland Emerging Technologies announces board appointments 52
Jan 16, 2017: Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cumberland Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cumberland Pharma to Acquire Vibative from Theravance Biopharma 12
Cumberland Pharma to Acquire Omeclamox-Pak from Gastro-Entero Logic 13
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 14
Cumberland Pharma and Poly Pharma Enter into Co-promotion Agreement 15
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 16
Cumberland Pharma Enters into Agreement with Gastoenterlogics 17
Cumberland Pharma Enters into Agreement with Piramal Critical Care 18
Cumberland Pharma Enters into Agreement with Clinigen 19
Cumberland And Harbin Gloria Enter Into R&D Agreement With Cumberland Emerging 20
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 21
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 22
Cumberland Pharma Enters into Licensing Agreement with Nordic Group 23
Cumberland Pharma Enters Into Licensing Agreement With Sandor Medicaids For Caldolor 25
Harbin Gloria Pharma Enters Into Licensing Agreement With Cumberland Pharma For Acetadote and Caldolor 26
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 28
Cumberland Pharma Enters Into Licensing Agreement With SOHO Industri Pharmasi For Caldolor 29
Cumberland Pharma Plans to Raise up to USD25 Million in Public Offering of Shares 30
Cumberland Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 31
Cumberland Pharmaceuticals Inc, Key Competitors 32
Cumberland Pharmaceuticals Inc, Key Employees 33
Cumberland Pharmaceuticals Inc, Subsidiaries 34

List of Figures
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Cumberland Pharmaceuticals Inc (CPIX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10165)販売に関する免責事項を必ずご確認ください。
★調査レポート[Cumberland Pharmaceuticals Inc (CPIX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆